FDA grants Breakthrough Therapy designation to ianalumab for Sjögren disease after the monoclonal antibody showed significant disease improvement.

HealthDay News — The rate of early termination or withdrawal in head and neck squamous cell carcinoma (HNSCC) clinical trials (CTs) has increased since 2000, with strategic decisions and poor ...

Prevalence, treatment utilization described for hypertension, diabetes mellitus, obesity, LDL-C, and cigarette smoking.

Strategy is feasible for advanced cancers; 157 regimens were administered to 210 patients, including 103 personalized combos ...

Higher rates of glaucoma therapy seen at increasing IOP levels, with cutoff of 22 mm Hg influencing clinician decision-making ...

However, relief does not translate into measurable improvements in visual task performance or tear film metrics ...

Accelerated aging and elevated mortality seen for women with most live births throughout their lives, nulliparous women.

More patients in FMD group met primary outcome of clinical response and prespecified secondary outcome of clinical remission.

Below is a review of novel drug and biological products approved by the Food and Drug Administration (FDA) in 2025. The list includes several groundbreaking therapies that are expected to change the ...

The FDA is expected to decide on treatments for allergic fungal rhinosinusitis, bipolar I disorder, Hunter syndrome, Leber hereditary optic neuropathy, ovarian cancer, and schizophrenia.

HealthDay News — Pharmacists and female pharmacy technicians have a higher risk for suicide than the general population, according to a study published January 8 in the American Journal of ...

Narcan Nasal Spray is an opioid antagonist that reverses the effects of opioids, including respiratory depression, sedation, and hypotension.